Become a part of the 2023 U.S. debut of Lift Events & Experiences, at the Moscone Center in San Francisco, from Wednesday, August 2 – Friday, August 4, 2023. The leader in Canada, Lift’s first conference over the border offers exclusive content, robust networking, and unparalleled new product discovery opportunities. The event is dedicated to the evolution of the cannabis industry, and brings to the U.S. Lift’s long-established and respected reputation for powerful cannabis events.

After proving its mettle in Vancouver and Toronto, the former Lift&Co. Expo will now simply be called ‘Lift’, reflecting its expanding footprint. Lift invites attendees for unique and immersive learning experiences in 2023, including Lift Vancuover (January 12-14, 2023), Lift Toronto (June 1-3, 2023) and at the new Lift San Francisco event (August 2-4, 2023). With Lift now expanding its coverage to the U.S., the ties between the U.S. West Coast and Western Canada’s long-thriving cannabis culture are expected to strengthen further.

“Lift welcomes everyone, from legacy participants to multistate operators to everyday folks who enjoy and respect the plant,” says Lift Events & Experiences Portfolio Lead, Lindsay Roberts. “We’re producing a year of shows that care for the specific needs of each segment of the cannabis community while inspiring an exciting future. To emphasize this commitment, we’re dropping our old ‘&Co. Expo’ moniker to put the focus simply on ‘Lift’ as we work to affect positive change across North America.”

Lift events are attended by cannabis industry veterans and fresh voices alike, always presenting valuable and updated information through speaker sessions and presentations on topics vital to the cannabis business and trade. Connect with cannabis experts, innovators, regulators, and leaders of the cannabis business community, build long-term business ties, and get discovered by potential investors on this robust networking forum.

Through one-on-one interactions and communication, the Lift team ensures that every company or individual attending the event is presented with an abundance of opportunities, including growers, brands and product delivery, advocacy and investment, legal/compliance, retailers, budtenders, enthusiasts and more.

For more information on Lift Events & Experiences, visit https://liftevents.com/.

• CubCrafters’ announcement about filing for Reg A qualification with the SEC was met with enthusiasm as investors pledged $5 million in reservations for 1 million planned shared in the first 48 hours following the announcement
• The company intends to use some of the infusion of funding to accelerate production rates as they are sold out through late-2024and anticipate taking orders for 2025 soon
• The backcountry aircraft market is expected to reach $11.9 billion by 2030
• CubCrafters company focuses on four main product lines – the Carbon Cub FX, NXCub, XCub, and Carbon Cub EX kits, and announced a new engine option in August 2022

The light and ultralight aircraft market is projected to grow from $7.5 billion in 2022 to $11.9 billion in 2030, driven by the number of backcountry enthusiasts growing on the heels of the COVID-19 pandemic (https://ibn.fm/xH1g2). “Light aircraft” is classified as any aircraft with a maximum gross takeoff weight of 12,500 pounds or less and are most commonly used for general aviation purposes. Best-in-class backcountry aircraft producer CubCrafters is leveraging the anticipated industry growth after announcing its intentions of a public offering under Reg A qualifications with the U.S. Securities and Exchange Commission (“SEC”).

Within the first 48 hours of the company’s announcement, CubCrafters was met with enthusiastic investor interest, with $5 million in reservations for 1 million planned shares, growing to over $25 million in reservations and is on track to reach its planned $50 million target as it awaits qualification for its listing with the SEC.

CubCrafters was founded in 1980 by Jim Richmond after a thorough fact-finding mission in Alaska, resulting in selling his home insulation business and switching to rebuilding Super Cubs. The company is driven by Jim’s vision and the ability to optimize performance potential of the Super Cub legacy. CubCrafters introduced its first new aircraft in 1999, the Piper/CubCrafters PA18, built under the FAA’s Spare & Surplus Rule.

The company focuses on four main product lines – the Carbon Cub FX, NXCub, XCub, and Carbon Cub EX kits. The models are built to be lightweight and powerful, with some emphasizing short take-off and landing capabilities, and others built for longer missions in unforgiving backcountry environments. Dominating this sector, the company has developed seven models that emphasize flexibility, including varied landing gear configurations such as nosewheel, tailwheel, floats, and skis.

In the Reg A announcement, Vice President of Sales and Marketing Brad Damm discussed how CubCrafters plans to use an infusion of funding to accelerate the production rate, making special note that the company has already sold out through late-2024 and is expecting to begin taking orders for 2025. (Source)

In August, the company debuted a new lightweight engine for its Carbon Cub model, improving the CC340 that made previously unheard-of short takeoff and landing performance possible for backcountry enthusiasts. The new CC363i F/P is a higher displacement fuel-injected engine with more horsepower than the CC340, according to CubCrafters. As the flight test program is nearing completion, new engines will begin shipping to customers, with priority given to those wishing to upgrade their existing kit aircraft order.

“This is an engine our customers have been specifically asking for, especially our kit aircraft customers. It’s simple to operate and has better overall performance than any of the other fixed-pitch engines we offer,” said Damm, who flew the first CC363i F/P equipped Carbon Cub (https://ibn.fm/Qmih4). “It’s smoother, more fuel efficient, and it cools better. Customers who choose this new engine are going to be pleased for sure.”

For more information, visit the company’s website at www.CubCrafters.com.

NOTE TO INVESTORS: The latest news and updates relating to CubCrafters Inc. are available in the company’s newsroom at https://ibn.fm/CUB

• California retail stores sold almost $5.3 billion worth of cannabis products in 2021 and reported a total tax revenue of approximately $1.3 billion
• California’s three licensing authorities issued 12,227 commercial cannabis licenses to businesses throughout the state during 2021
• San Diego has approved a social-equity program, joining the ranks of other California cities and counties that have implemented them since 2018, utilizing tax revenues from the cannabis industry
• REZYFi is the first cannabis mortgage company in the United States – a market where most traditional lenders are still reticent to enter

On November 8, 2016, California voters approved cannabis for recreational use. Since then, the market has continued to increase in revenue, and it is expected to make up 61.5% of the overall market, according to the University of California Agricultural Issues Center. In 2021, California retail stores sold almost $5.3 billion of cannabis products, indicating a 20% growth over 2020 and over 20% of legal sales in the United States. The total tax revenue reported by the cannabis industry was about $1,317.6 million in 2021, including approximately $680.4 million in excise tax.

As of December 2021, California’s three licensing authorities issued 12,227 commercial cannabis licenses to businesses throughout the state – including 8,504 cultivators, 915 manufacturers, 842 retailers, 362 delivery services, 1056 distributors, 308 microbusinesses, 152 transporters, 46 event organizers, 42 testing laboratories (https://ibn.fm/e6dbB).

The San Diego Union-Tribune reported that the San Diego City Council recently approved a social-equity program for the city’s cannabis industry, including start-up loans, fee waivers, and other business assistance. Although San Diego was the first California city to approve an adult-use cannabis licensing plan in 2017, the plan did not include social equity provisions.

The social-equity plan requires that applicants meet various criteria:

• Conviction of a cannabis-related crime or having a family member convicted of a cannabis crime after January 1, 1994, within the San Diego city limits; and be a current or former resident – for at least five cumulative years between 1980 and 2016 – including Barrio Logan, Linda Vista, southeastern San Diego, Encanto, Golden Hill, North Park, City Heights, the College Area, or San Ysidro.
• Applicants must also meet two additional criteria, including a household income below 80% of the area median income ($106,900 for a family of four); lost housing in San Diego through eviction, foreclosure, or subsidy cancellation after 1994; attended school in the San Diego Unified School District for at least five years between 1971 and 2016; or placed in the foster care system at any time between 1971 and 2016.

Since the state started allowing equity plans in 2018, Long Beach, Los Angeles, Oakland, Palm Springs, Sacramento, and San Francisco have launched such programs, including Humboldt, Lake, and Mendocino counties, which have programs funded by state cannabis taxes (https://ibn.fm/3X0ZK).

Despite the massive market growth recently, most traditional lenders are reticent to serve the state-licensed cannabis industry, but one company, REZYFi, is positioned as the first cannabis mortgage banker in the United States. REZYFi services the needs of both traditional and non-traditional consumers and businesses. The company is targeting markets that include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

REZYFi operates under two wholly owned subsidiaries – REZYFi Lending and ResMac Inc. REZYFi Lending primarily addresses emerging real estate-related financing opportunities. ResMac is the Company’s traditional mortgage origination, correspondent, and servicing operation. As a whole, REZYFi is using its corporate strengths as a foundation for diversifying its approach to capitalize on growth in multiple verticals in the years to come.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Cyberattacks on SMBs have increased due to the changing network landscape due to the increase in remote and in-office workers relying on cloud environments, mobile devices, software applications, and third-party suppliers to conduct business
• SideChannel announced its preliminary revenue of $4.6 to $4.8 million for the fiscal year that ended September 30, 2022 – a 64% to 71% year-over-year increase from the company’s revenue of $2.8 million during the fiscal year 2021
• SideChannel continues to expand its service offerings, workforce, and customer base and has attracted over 20 vCISOs to serve across industries, including fintech, biotech, healthcare, manufacturing, legal defense, and technology services

Cybersecurity protects networks, information, and personal data from being vulnerable to cyberattacks. According to ReportLinker, the global cybersecurity market was valued at $150.37 billion in 2021 and is expected to reach a value of $312.02 billion by 2027, growing at a CAGR of 13.37%. The trends driving growth in this market include BYOD, AI, IoT, and machine learning; coupled with the significant reduction in device costs, increasing the number of connected network devices is driving the growth of the market. The emergence of 5G is also expected to expedite the use of connected devices in the industry, pushing toward industrial revolution 4.0 (https://ibn.fm/siJ6Y).

Reports have shown that cyberattacks on SMBs (small and mid-sized businesses) have increased due to the changing network landscape, with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications, and third-party suppliers to conduct business. For mid-market companies looking to increase their cybersecurity, SideChannel (OTCQB: SDCH) simplifies cybersecurity by matching these companies with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time chief information security officer (“CISO”).

SideChannel’s team of virtual CISOs (“vCISOs”) offers 400-plus years of combined experience in cybersecurity – honing their skills and abilities in corporations like Anthem, Dick’s Sporting Goods, BestBuy, TD Bank, and the Pentagon. SideChannel lends its talent to clients, creating value in its bespoke cybersecurity program, which is perfectly sized for the growing enterprise.

Prior to the company’s participation in the LD Micro Main Event XV at the end of October 2022, SideChannel announced that preliminary revenue reached $4.6 to $4.8 million for the fiscal year that ended September 30, 2022 – a 64% to 71% year-over-year increase from the company’s revenue of $2.8 million during the fiscal year 2021. SideChannel also announced securing six new clients with a combined annual revenue value of $1.3 million and signing renewal contracts with existing clients. The company expects to recognize the revenue associated with the new clients and signed renewals within 12 months of the signature date, along with the related incremental engineering, products, and services revenue.

“We are winning exciting new recurring revenue customer agreements with well-known middle-market names across diverse industries. For example, our wins include engagements with names such as Handshake, Veza, Kiava, Riot Blockchain, and Lightcast,” SideChannel CEO and Founder Brian Haugli said (https://ibn.fm/Yq7O0). “Additionally, we are typically generating substantial incremental revenue on the engineering and services associated with these agreements, further increasing the value of our new customer engagements even beyond the initial contracted services.”

SideChannel continues to expand its service offerings, workforce, and customer base and has attracted over 20 vCISOs to serve across industries, including fintech, biotech, healthcare, manufacturing, legal defense, and technology services. To date, the company has created more than 50 multi-layered cybersecurity programs for its clients – requiring it to expand its sales force from one position to five in 2022. This reflects the large and growing sales funnel of SMB customer opportunities for its vCISO and cybersecurity services. SideChannel is committed to creating the solutions necessary for SMBs to protect their data and assets in the ever-changing cybersecurity market landscape.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastoma
• CNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in France
• CNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patients
• The company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025
• The FDA has granted Berubicin Fast Track and Orphan Drug status, speeding the possibility of marketing the drug following the potentially pivotal clinical review

Innovative brain tumor therapy developer CNS Pharmaceuticals (NASDAQ: CNSP) is reporting continued expansion of the number of clinical site launches for its evaluation of the company’s lead product candidate for treating recurrent glioblastoma multiforme (“GBM”). CNS Pharmaceuticals noted in a recent update about its anti-cancer drug candidates and its third quarter financial results that the potentially pivotal trial for its lead candidate — Berubicin — has begun patient enrollment and dosing in France, bringing its operational tally to 29 of 68 clinical sites now enrolling patients across the United States and Europe. “This expansion into Europe drives us toward our goal of interim analysis, expected in mid-2023, which we believe has the potential to be (a) transformational milestone,” CEO John Climaco stated in a company news release providing the update (https://ibn.fm/ULeIw). “Moving forward, we are focused on building momentum and advancing this important program across the finish line.” GBM is an incurable brain cancer that is diagnosed in approximately 13,000 U.S. patients alone each year, and that number is expected to grow. Up to 50 percent of original malignant tumors of the central nervous system (“CNS”) are glioblastomas, and those patients have an average survival time of about a year after diagnosis — only 10 percent or less survive to five years (https://ibn.fm/b2Imf). “Unfortunately, there is a paucity of effective treatment options for glioblastoma, despite it being the most common primary brain tumor in adults,” an Oncology Nursing News report on radiation’s effects on overall survival (“OS”) states (https://ibn.fm/3p1pp). While radiation can significantly improve OS in newly diagnosed GBM patients, as the cancer recurs (which it generally does), reirradiation combined with a standard drug treatment improves progression-free survival (“PFS”) for a few months but not OS, the report states, citing findings published in the Journal of Clinical Oncology. The need to find an effective solution for surviving such a common brain cancer has created a competitive search for a better treatment. CNS Pharmaceuticals’ development of anti-cancer drug candidates is spurred by Berubicin’s performance in a safety trial conducted in 2006 by the drug’s initial developer, Reata. That initial small trial involved two dozen evaluated patients, one of whom has remained free of brain cancer during the intervening years. And nearly half of the trial’s other patients experienced a statistically significant improvement in clinical benefit (https://ibn.fm/a8hbj). CNS Pharmaceuticals’ expansion of clinical trials evaluating Berubicin included initial reports of its performance against cells in the lab and rose to the level of a global human trial comparing Berubicin responses to those of patients treated with Lomustine, another GBM standard of care. In addition to the United States and France, trial site initiations are being advanced in Italy, Spain and Switzerland. Berubicin has received Fast Track and Orphan Drug Designation from the U.S. Food and Drug Administration (“FDA”) to help speed its potential reviews and marketability as the trial is completed. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Renewable energy movement growing in construction sector, backed by solar panel and geothermal technology
• GeoSolar’s SmartGreen(TM) Home system offers a total-home makeover, including solar panels and geothermal ground loops
• Additional SmartGreen(TM) features include building envelope optimization, and upgrades to insulation, windows, and lighting systems
• SmartGreen(TM) can be adapted to new construction and existing buildings within weeks
• GeoSolar conducting Regulation A+ capital raise

Environmental degradation, energy price instability, and a declining economy paint a grim picture for many people across the world. Despite the negativity, a renewable energy movement is taking shape, backed by companies like GeoSolar Technologies (“GST”), a climate technology company based in Colorado. GeoSolar’s SmartGreen(TM) Home system offers multiple solutions to the planet’s growing challenges. The technology provides a total-home makeover that replaces fossil fuel-based energy systems with solar panels and geothermal ground loops to provide heating, air conditioning, and electricity to power appliances. Energy efficiency is also maximized in a SmartGreen(TM) home by tightening the building envelope and upgrading insulation, windows, and lighting systems. Backed by a successful track record across multiple test homes in Colorado, SmartGreen(TM) recently earned top scores on the Home Energy Rating System (“HERS”) Index – the industry’s gold standard for calculating energy performance and efficiency. Besides being more energy efficient, HERS-rated homes have a higher property value according to the North Carolina Building Performance Association (https://ibn.fm/vPsfo). Energy prices are rising across the world, leading to political instability. SmartGreen(TM) technology helps insulate owners from price shocks by drastically reducing or eliminating utility bills and providing energy independence. SmartGreen(TM) homes also offer an EV charging station entirely powered by photovoltaic solar panels, giving homeowners an additional way to transition away from fossil fuels. Renewable energy systems like SmartGreen(TM) may become more affordable for homeowners across the U.S. through the Inflation Reduction Act of 2022 (https://ibn.fm/KXrl6). Rebates offered by the legislation include new electrical panels and heat pumps, along with a 30% solar tax credit. In addition to subsidizing solar panels, the Department of Energy announced a program to reduce geothermal system costs by 90% to $45 per megawatt hour by 2035 (https://ibn.fm/xo1YD). GeoSolar aims to market SmartGreen(TM) to over 120 million homes across the U.S. with options to build the system into new construction or adapt it to existing buildings. As part of its strategy, the company recently gained approval from the US Securities and Exchange Commission to conduct a Regulation A+ capital raise that allows the public to participate with a minimum $300 investment. For more information on GeoSolar’s Regulation A+ capital raise, please visit https://www.manhattanstreetcapital.com/geosolar-technologies-inc. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• MetAlert’s management team is highly experienced (several previous exits) in the tech, apparel, and wearable medical device industries, with significant management ownership (70%+) in MLRT
• The company operates in a large and growing global market in terms of potential revenue ($20-$50+ per month) and number of users (34+ million), with a potential impact on hundreds of millions
• The recent pandemic created an emphasis on health monitoring, especially for at-risk consumers/patients
• The recent pandemic negatively impacted the supply chain and shipping, creating a backlog of orders, but recent months’ activity suggests that the supply chain and shipping issues will be resolved before year-end
• In September 2022, the company completed rebranding from GTX Corp. and debuted a new ticker symbol, ‘MLRT’
• In October 2022, GPS SmartSoles were featured on the Gadget Guys show on the CW, reaching 3.2 million households across the U.S.
• In November 2022, MetAlert announced that its Canadian distributor had launched the new 4G GPS SmartSoles product

MetAlert (OTC: MLRT) is a pioneer in location sensitive health monitoring devices (estimated $47 billion industry in 2021) and wearable technology products (industry forecast to reach $174 billion by 2030). With over 20 years of experience and an extensive patent portfolio (30+), MetAlert is a leader for consumers/patients afflicted with Alzheimer’s, dementia, and autism (“ADA”). This market represents approximately 2.9% of the world’s population (approximately 34 million people in 24 developed countries). Due to specific behaviors (problems with memory, adversity to wearing unknown items, etc.) of consumers/patients in this market segment, traditional products, such as an iPhone or Fitbit, are not a practical solution. This has created a significant market with very few competitors for MetAlert. MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, and selling products and services in GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. The company offers a global end-to-end hardware, software, and connectivity solution, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products and enterprise applications. Using its award-winning, patented GPS SmartSole(R) as a hub for collecting and transmitting data to the cloud in real-time, MetAlert is expanding its value proposition to consumers and increasing its revenue per user (“RPU”) while creating the largest database of health statistics for ADA consumers/patients. MetAlert generates revenue from product sales, recurring subscriptions, intellectual property (“IP”) licensing, and professional services. The company has international distributors servicing customers in over 35 countries and is an approved U.S. military government contractor. Its customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. The company is headquartered in Los Angeles, California, with a sales office in London, England, and distributors across the globe. Products

• GPS SmartSoles(R) HUB (launched Q4 2022) is a GPS/BLE-equipped insole that allows remote monitoring, data collection, and encrypted data transmission to the cloud.
  • Telehealth (available Q4 2022) allows access remotely to doctors and other health professionals on an as-needed basis. This service will also function as the prescribing doctor once Medicare reimbursement codes are established.
  • Concierge (available Q4 2022) provides 24/7/365 enhanced emergency response that coordinates with all relevant parties to quickly detect false alarms and escalate response as needed.
  • Bluetooth Enabled Devices (available Q1 2023) include third-party devices that collect vitals and other health data and connect with the GPS Smartsoles(R) HUB.
  • Artificial Intelligence (available Q1 2023) software will evaluate the Teradata of health information identifying trends and respond to preestablished alert thresholds.
• Take-Along Tracker is a small GPS tracking device – less than three inches long – that works with 4G cellular service and will have the same “HUB” functionality as the GPS Smartsoles(R). This versatile and affordable mini tracker boasts super long battery life, with up to 14 days of operation per charge.
• RoomMate(TM) is a wall-mounted alert system that detects and alerts caregivers about patient behavior that could lead to falls and injuries. The system features 3D infrared and wall-mounted sensors, eliminating the need for any other physical installation or wearables. RoomMate(TM) offers patient privacy by design. Images are not stored, but all actions are logged. It’s a unique solution for looking after patients without intruding on their personal space.

Market Outlook According to Grand View Research (Patient Monitoring Devices Market Size & Share Report, 2030), the global patient monitoring devices market size was valued at $47.0 billion in 2021 and is expected to expand at a compound annual growth rate (“CAGR”) of 7.8% from 2022 to 2030. The expansion of the industry can be attributed to the rise in demand for monitoring devices used to measure, distribute, record, and display a variety of biometric data, including blood pressure, temperature, and blood oxygen saturation level. The growing number of chronic disorders, such as diabetes, stroke, and kidney disease, are driving the demand for patient monitoring devices. For instance, according to the World Health Organization (“WHO”), about 422 million people globally have diabetes. Likewise, the number of asthma and chronic obstructive pulmonary disease patients (“COPD”) is increasing rapidly. According to the WHO, around 235 million people suffer from asthma. As a result, peak flow meters, which are used to gauge respiration rate, are increasingly used. The market for patient monitoring devices is driven by the simplicity with which it is handled, transported, and remotely accessible. Major market players are engaging in a variety of tactics to expand the industry, including partnerships, cooperation, innovation, launches, and mergers. During the COVID-19 outbreak, social segregation and quarantining procedures were put into place worldwide. Many people avoided regular hospital visits as a result. Many people now need routine home temperature and oxygen level monitoring to maintain track of their health, thereby demanding monitoring devices at home. Various government programs are supporting the pandemic outbreak. The FDA has granted Emergency Use Authorizations (“EUAs”) for a few wearables and patient monitoring devices to improve access to medicines, monitor patients more closely, and lessen the risk of SARS-CoV-2 exposure to medical professionals during the COVID-19 pandemic. The growing popularity of wearable and remote patient monitoring devices is another factor fueling the market’s expansion. By fusing clinical symptomology with vital indicators, wearable technology helps in the diagnosis of many chronic diseases. Thus, there has been a dramatic rise in the usage of wearable technology to combat COVID-19. The wearable medical device market is anticipated to reach $174.48 Billion by 2030, expanding at a 27.1% CAGR during the forecast period (2022-2030), according to Market Research Future. MetAlert identifies the total addressable market for its wearable patient monitoring tech for those with Alzheimer’s, dementia, and autism at more than 34 million potential patients in North America, Europe, South Africa, and Asia. Management Team Patrick E. Bertagna is Founder, CEO and Chairman at MetAlert. He began his career in apparel sales in 1983 and was promoted to national sales manager within two years. In 1986, he founded his first company importing apparel from Europe and selling to U.S. retailers from JCPenney to Neiman Marcus. He has founded several technology and apparel companies, including MetAlert in 2002, which he took public in 2008. He attended Cal State University Northridge with a business major and a psychology minor. Louis Rosenbaum is COO of MetAlert. He co-founded Global Trek Xploration and was an initial investor in MetAlert. He has successfully started companies in multiple industries, including apparel, environmental services, and the music industry, achieving annual revenues in the multi-millions of dollars. He previously was president of Elements, a women’s apparel company, and of Advanced Environmental Services. Alex McKean is CFO at MetAlert. He is also the CFO of Encore Brands Inc., a position he has held since 2009. He has held positions as Controller and VP of Finance at 24:7 Film and InternetStudios.com, Director of FP&A/SVP at Franchise Mortgage Acceptance Company, Corporate Accounting Manager/Treasurer of Polygram Filmed Entertainment and Assistant Treasurer/Controller for State Street Bank. He holds an International MBA from Thunderbird School of Global Management and undergraduate degrees in business and political science from Trinity University. For more information, visit the company’s website at www.MetAlert.com. NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• Arizona is one of the most attractive mining jurisdictions in the world and hands down the biggest producer of copper in the U.S.
• Arizona Metals’ flagship project, Kay Mine, is surrounded by 60 past producing underground VMS copper-gold-zinc-silver mines
• 72,000 meters have been drilled to date in Phases 1 and 2 at Kay Mine, to prove historic resource estimates and with CDN$60 million in the bank, Arizona Metals is ready to complete Phase 2 and initiate Phase 3 drilling now that Bureau of Land Management (“BLM”) has approved drill pads

Arizona is the United States’ largest producer of copper without question, as the state was responsible for 71% of the country’s copper production in 2021. Looking ahead, there are clear signs that Arizona will continue to dominate a market expected to see increasing demand owing to the rise of electric vehicles. In its bid to add its name to Arizona’s rich mining history, Arizona Metals (TSX: AMC) (OTCQX: AZMCF) hit a big milestone at the end of October that paves the way for resources and reserves at its expansive project north of Phoenix. Laden with copper, gold and other metals, Arizona is ranked 2nd out of 77 jurisdictions for investment attractiveness by the venerable Fraser Institute. It is not without reason that the state is a host to mines and projects owned by some of the most recognizable names in the mining business, such as Rio Tinto, Freeport, and Hudbay. Arizona Metals has two projects, Kay Mine and Sugarloaf Peak, in prolific mining districts, both of which have substantial historic resources that the company is aiming to bring current and expand upon. Kay Mine is the flagship project in Yavapai County, covering 1,300 acres on a combination of patented and Bureau of Land Management (“BLM”) claims. The project is 100% owned by Arizona Metals, not subject to any royalties, and is surrounded by 60 past producing underground VMS (Volcanogenic Massive Sulphide) copper-gold-zinc-silver mines. VMS deposits are known to be rich in metals and often found in clusters. Glencore’s Kidd Mine just north of Timmins, Ontario, Canada is the posterchild for the potential of VMS deposits. It has been producing for 56 years and has turned out over 9 million tonnes of zinc (“Zn”), 3.4 million tonnes of copper (“Cu”), and 12,000 tonnes of silver (“Ag”). It is the deepest base metal mine in the world, with mining activities ongoing at 9,600 feet (nearing 2 miles) below surface. Arizona Metals’ Kay Mine Deposit is unique in that it is a gold-rich VMS deposit; there are very few of these left in the world that are not currently in production or owned by major producers. About an hour to the north of Kay Mine, Phelps Dodge’s United Verde Mine produced 30 million tonnes at 5% Cu from an open pit and 4 million tonnes at 10% Cu from underground mining. About an hour to the southeast of Kay, is Rio Tinto’s vaunted Resolution Mine that is estimated to produce up to 40 billion pounds of copper over 40 years when it comes online. Kay Mine has an historic resource estimate* of 5.8 million tonnes at 2.8 grams per tonne (g/t) gold (“Au”), 2.2% Cu, 3.03% Zn, and 55 g/t Ag, according to work completed by Exxon Minerals in 1982. In a Phase 1 drill program, Arizona Metals spent CDN$25 million drilling 72,000 meters across 2-1/2 years to better understand the Kay Mine deposit. The drilling returned a spate of positive data, including intercepts of 43.1m grading 3.94% CuEq (copper equivalent), including 15.2m of 6.7% CuEq, from a depth of 341m and 38.4m grading 2.9% CuEq, incl. 12.5m of 6.0% CuEq, from a depth of 385m. The Au-Zn Discovery Zone hit 93.3m grading 8.3 g/t AuEq (gold equivalent), including a sub-interval of 17.5m grading 29.6 g/t AuEq. About 200m below this, drilling intersected another copper-rich zone of 125.3 m at 3.2% CuEq. Grades and widths of this magnitude have typically only been encountered historically in world-class deposits and mines. All equivalent calculations are after assumed mining recoveries. The exploration work has shown Kay Mine to be a steeply dipping VMS deposit defined from a depth of 60 meters to at least 900 meters. Mineralization remains open for expansion on strike and at depth. Particularly compelling is the fact that drilling to date has only explored about 3% of the prospective mineral horizon. That is about to change, as Arizona Metals has now received permit approval from the Arizona BLM for two new drill pads, located approximately 1,200 meters west of the Kay Mine deposit. Arizona Metals is fully funded with approximately CDN$60 million in cash at the end of the first half of the year as it continues its Phase 2 and initiates its Phase 3 drill programs that will continue to test high priority targets at Kay, as well as the 97% of the untested horizon. The company has earmarked CDN$27 million to drill 18,000 meters in the Phase 2 programs, followed by ~76,000 meters in a Phase 3 drilling program focusing on its Central and Western targets in the search for new discoveries within the vicinity of the known deposit. Construction of the drill road for the Central target (located 500 meters west of the Kay Mine deposit) is complete. Road construction for the Western target will begin upon confirmation of BLM acceptance of the company’s posted bond by year end with drilling to commence in Q1 2023. Since the company was listed in 2019, equity research analysts at the Bank of Montreal, Scotiabank, National Bank, Stifel, Clarus Securities, Beacon Securities and Agentis Capital have published reports on Arizona Metals with 12-month target prices ranging from CDN$$6.50 to $10.50 per share. * The historic estimate at the Kay Mine was reported by Exxon Minerals in 1982. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re- drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource. Full Disclosure: Arizona Metals Corp. is an Investor Brand Network marketing client. For more information, visit the company’s website at www.ArizonaMetalsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to AZMCF are available in the company’s newsroom at https://ibn.fm/AZMCF

• New Chief Medical Officer will play a major role in defining best paths to adoption, clinical strategies, and partnerships
• Dr. Fitzgerald serves as director of the Center for Cardiovascular Technology and of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School
• Dr. Fitzgerald brings impressive expertise in the clinical, research and industry sectors

In a display of its commitment to offering innovative, high-quality products and services, cardiac tech company HeartBeam (NASDAQ: BEAT) has named a world-renowned interventional cardiologist with an impressive breadth of experience as its Chief Medical Officer (https://ibn.fm/pN1kf). Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help HeartBeam continue to develop the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. “We are thrilled to have Dr. Fitzgerald, one of the world’s preeminent opinion leaders in cardiology and digital health, join the HeartBeam leadership team and play a major role in defining best paths to adoption, clinical strategies, and partnerships to advance our products in the market,” said HeartBeam founder and CEO Branislav Vajdic, PhD. “In addition to his cardiovascular clinical and research expertise, Dr. Fitzgerald has a rich history of developing successful collaborations with partners in the industry and has developed deep connections across the investment and medical communities.” Dr. Fitzgerald joins HeartBeam after gaining invaluable experience in the clinical, research and industry sectors. An accomplished inventor, entrepreneur, and investment-fund founder, Dr. Fitzgerald is serving as director of the Center for Cardiovascular Technology and director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is a professor emeritus from the Department of Medicine (Cardiology) at Stanford University and has been integrally involved in more than 175 clinical trials. His expertise as an author is profound, with more than 650 manuscripts or chapters to his name. He is also a prominent speaker and trainer, having lectured around the world and trained more than 150 post-doctoral candidates in engineering and medicine. Outside of the academic world, Dr. Fitzgerald has been principal and founder of 24 medical-device companies, leading 18 of those from start-up stage to becoming medium-cap or large-cap life-science companies. In addition, he cofounded Israeli-based TriVentures, an incubator/venture fund targeting early-stage medical technology and digital health. Finally, for the past two decades, Dr. Fitzgerald has served as a consultant to the U.S. Food and Drug Administration (“FDA”), where his focus has been on medical technology and data-driven health analytics. With his PhD in electrical engineering and extensive background, Dr. Fitzgerald is imminently qualified for his new position. “HeartBeam’s focus on bringing novel diagnostic tools to cardiac patients, especially those with a high risk for a heart attack, could have a significant, positive impact on medical outcomes and quality of life for patients while potentially saving healthcare dollars,” said Dr. Fitzgerald. “I look forward to supporting the planned advancement of the Company’s rich product pipeline to deliver comprehensive cardiac care for patients anytime, anywhere.” HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to quickly and easily determine if symptoms are due to a heart attack so care can be expedited, if required. HeartBeam has two patented products in development: HeartBeam AIMI(TM) is software for acute-care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the FDA for marketing in the USA or other geographies. For more information, visit the company’s website at www.HeartBeam.com. NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementia
• The animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancements
• Previous independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairment
• The laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is working on implementing its commercial strategies around the highly patented DehydraTECH(TM) drug delivery technology, with these strategies firmly anchored in and driven by R&D studies. According to company CEO Chris Bunka’s letter to shareholders, the company’s plans for 2022 included the launch and completion of several major applied studies as well as many smaller programs (https://ibn.fm/3nKvC). In line with these plans, the company has so far launched – and announced the successful results of – its most comprehensive hypertension study yet, HYPER-H21-4 (https://ibn.fm/CucaJ), and has received an Independent Review Board (“IND”) approval to commence its planned human oral nicotine study (https://ibn.fm/HFvwF). At the same time, Lexaria has also set out to study the effect of DehydraTECH-processed cannabidiol (“CBD”) on diabetes and, more recently, announced it would commence its study program DEM-A22-1. A dose-ranging, two-month program involving 32 Long Evans rats dosed with DehydraTECH-CBD, DEM-A22-1 is Lexaria’s first-ever study to investigate whether DehydraTECH-CBD may potentially have therapeutic utility against dementia. It will be undertaken by a leading, third-party testing lab in Canada, with the laboratory work expected to complete in late January 2023 and results reported likely in April 2023. “The study is a novel object recognition test which is widely used to assess memory in rodents, and is being utilized to investigate whether CBD enables cognitive performance enhancements in this model, potentially of utility in dementia treatment,” the company’s November 10 press release explains (https://ibn.fm/U9vSy). CBD has been the subject of many studies evaluating the effects of the compound on neurogenerative diseases and dementia (https://ibn.fm/8s2sO). One such study, published in 2014 in the Journal of Alzheimer’s Disease, demonstrated CBD’s ability to prevent the development of a social recognition memory deficit in AD (Alzheimer’s disease) transgenic mice (https://ibn.fm/deJQr). Social or facial recognition memory reflects the ability of social animals – including mice – to recognize and remember familiar individuals of the same species (https://ibn.fm/Qivbd). A deficit, therefore, reflects an inability to recognize familiar faces. Face or social recognition deficits are frequently reported in patients with AD and are attributed to memory impairment. Therefore, the findings from the 2014 study suggest that CBD prevents the development of this symptom. For Lexaria, however, such findings are only part of the key motivators to commence the animal study on dementia. Others include the fact that the company has previously conducted efficacy studies evaluating DehydraTECH-CBD in humans with hypertension, revealing that the compound does not have any severe side effects and lowers human blood pressure (“HBP”). Coincidentally, a causal relationship exists between HBP and a type of dementia called vascular dementia – people with HBP are more likely to develop vascular dementia because of HBP-induced reduced blood flow to the brain. Moreover, the company has demonstrated in animal studies that DehydraTECH-CBD crosses the blood-brain barrier (“BBB”) much more effectively than originally thought possible. Ordinarily, the BBB blocks entry into the brain of most drugs in circulation, making it difficult to develop treatments for brain diseases. By crossing this barrier, however, DehydraTECH-CBD lends itself to science as a potential treatment for brain diseases such as dementia. Against this backdrop of favorable conditions, Lexaria is excited to investigate whether DehydraTECH-CBD might have some therapeutic benefits on dementia. The move and results, if positive, will usher the company into a burgeoning dementia drug market that analysts at Acumen Research and Consulting project will grow from $15.5 billion in 2021 to an estimated $32.3 billion by 2030, representing an 8.7% CAGR from 2022 to 2030 (https://ibn.fm/2epjA). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX